Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Enorama Pharma AB (publ) resolves to postpone the planned extraordinary general meeting

Enorama Pharma
Read the release

The board of directors of Enorama Pharma AB (publ), reg. no. 556716-5591, has resolved to postpone the extraordinary general meeting which was scheduled for Wednesday 11 March 2026 to Friday 20 March 2026.

Due to the above, the board of directors has resolved to withdraw the notice of the extraordinary general meeting scheduled for Wednesday 11 March 2026 in its entirety, and no general meeting will therefore be held on this date. Notice of extraordinary general meeting on Friday 20 March 2026 at Advokatfirman Delphi's premises at Nordenskiöldsgatan 11 A, 211 19 in Malmö will be sent separately later.

CONTACT

Enorama Pharma AB (publ)

Bengt Jönsson, acting CEO

info@enorama.se

Strandvägen 7A, 114 51 Stockholm.

www.enorama.se

Enorama Pharma AB is listed on Nasdaq First North Growth Market.

The company's Certified Adviser is Tapper Partners AB, +46 (0)70 44 010 98, ca@tapperpartners.se.

ABOUT ENORAMA PHARMA

Enorama Pharma's vision is to be a leading global producer and supplier of consumer-friendly, oral nicotine products. The company intends to expand through product and brand development and by establishing strategically important collaborations. For more information, visit www.enorama.se.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.